JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Quidel Corp

Fechado

23.63 -1.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23.46

Máximo

24.42

Indicadores-chave

By Trading Economics

Funcionários

6,600

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+82.68% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-76M

1.7B

Abertura anterior

25.58

Fecho anterior

23.63

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 21:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 de ago. de 2025, 21:21 UTC

Ganhos
Grandes Movimentos do Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 de ago. de 2025, 20:45 UTC

Ganhos

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 de ago. de 2025, 21:30 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 21:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 de ago. de 2025, 21:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 20:25 UTC

Conversa de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss $938M >RIG

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss/Shr $1.06 >RIG

4 de ago. de 2025, 20:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 de ago. de 2025, 20:15 UTC

Ganhos

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 de ago. de 2025, 20:13 UTC

Ganhos

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 de ago. de 2025, 20:09 UTC

Ganhos

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 de ago. de 2025, 20:06 UTC

Ganhos

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 de ago. de 2025, 19:41 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 de ago. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 de ago. de 2025, 19:07 UTC

Conversa de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 de ago. de 2025, 18:27 UTC

Conversa de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

82.68% parte superior

Previsão para 12 meses

Média 41.67 USD  82.68%

Máximo 60 USD

Mínimo 27 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

4

Comprar

3

Manter

1

Vender

Informação Financeira

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.